The North American Neuroendocrine Tumor Society (NANETS) is pleased to announce the Neuroendocrine Tumor Research Foundation (NETRF) Board of Directors has approved funding for the Basic/Translational Science Investigator (BTSI) Award for 2017 presented by NANETS. The 2017 award will be announced at the NANETS 10th annual symposium, to be held October 19-21 in Philadelphia, PA.

The purpose of the BTSI Award is to encourage scientists at the end of their fellowship or beginning their faculty appointment to pursue basic and/or translational research focused on neuroendocrine tumors. The two-year award provides $50,000 in funding each year, which is directed to the investigator’s sponsoring institution. NETRF funds this award with the generous support of the Margie and Robert E. Petersen Foundation.

“NANETS is grateful for the support of the Neuroendocrine Tumor Research Foundation in making the BTSI Award available to our members at a career crossroads,” said David Metz, M.D., chair of the NANETS Board of Directors. “We partnered with them on this award for the first time in 2016, and we hope this partnership continues for many years to come.”

“We are grateful to the Petersen Foundation and honored to collaborate with the North American Neuroendocrine Tumor Society, to fund research that will help us crack the code of neuroendocrine tumors, in pursuit of cures for all NET patients” said Ron Hollander, executive director of NETRF.

The North American Neuroendocrine Tumor Society is a society of medical professionals with extensive experience in neuroendocrine tumor (NET) disease. The only one its kind in North America and designed by medical professionals on the front lines of the disease, NANETS is a not-for-profit organization founded in 2007 with the mission of improving neuroendocrine tumor (NET) disease management through increased research and educational opportunities.

The Neuroendocrine Tumor Research Foundation is a charitable organization whose mission is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers. Since its inception, the Foundation has awarded more than $18 million in large-scale, multi-year research grants to leading scientists at renowned research institutions in the U.S. and abroad